Market Research Blog – Page 1925 – New Product Development

IgA Nephropathy Market Projected to Reach USD 85 Billion by 2033, Growing at 7.5% CAGR | FMI Study

The IgA Nephropathy Market, a type of kidney disease, is poised for significant growth in the coming decade. According to a recent study by Future Market Insights (FMI), the market is expected to reach a value of USD 85 billion by 2033, reflecting a steady increase with a Compound Annual Growth Rate (CAGR) of 7.5% during the forecast period (2023-2033).

Key factors such as the high prevalence of kidney diseases, rising R&D activities, increasing investments by market players, and technological innovations are anticipated to significantly drive market growth.

Moreover, the growing number of initiatives undertaken by the government to provide various facilities, such as reimbursement for diagnostic tests is a major factor likely to boost the market.

Request for a sample: https://www.futuremarketinsights.com/reports/sample/rep-gb-16217

The COVID-19 pandemic has been associated with increase in hospitalization and infection hotspots around the country. There were at least three separate waves of COVID-19 around the world by June 2021 that put a significant strain on hospital resources, especially labor and availability of dialysis equipment & supplies. In addition, the COVID-19 pandemic has affected healthcare services for renal disease patients. Social distancing and lockdown were mandate norms, globally, leading to temporary closure of other medical services. The diagnosis of several renal diseases deferred during the pandemic due to suspension of non-urgent visits and testing services.

On the other hand, increasing awareness regarding IgA nephropathy is expected to create lucrative opportunities for the market growth. For instance, In the U.S., an estimated 37 million adults have kidney disease. Major risk factors for the disease are high blood pressure and diabetes as well as heart disease, obesity, & family history of kidney disease. In addition, North America and Asia Pacific are two major regions contributing to the IgA nephropathy market.

Key Takeaways from the IgA Nephropathy Market Study

IgA Nephropathy market to garner US$ 85 Billion by the end of 2033.
IgA Nephropathy market to register a positive CAGR of 7.5% in the forecast period 2023-2033
By end user, the hospital’s segment is expected to hold 40% of the market share in 2023 for the IgA nephropathy market.
By diagnosis, the urine tests segment is projected to witness significant a CAGR of 7.5% during the forecast years.
North America is expected to possess a 40% market share for the IgA nephropathy market in 2023.
Asia Pacific is expected to hold a 35% market share for IgA nephropathy market share in 2023.

“Growing prevalence of kidney related problems along with research and development for manufacturing medication is favoring the growth of IgA nephropathy market” states a FMI analyst

IgA Nephropathy Market Competitive Landscape

Some of the key companies in the IgA Nephropathy market include Calliditas Therapeutics AB, Travere Therapeutics, Inc., Omeros Corporation, Novartis Pharmaceuticals, Chinook Therapeutics, Inc., Vera Therapeutics, Inc., Otsuka Pharmaceutical, and others

In June 2021, Novartis Pharmaceuticals announces iptacopan met Phase II study primary endpoint in rare kidney disease IgA nephropathy (IgAN).
Chinook Therapeutics, Inc, a key player in the IgA nephropathy market is focusing on diagnosing the causes of the ailment and offering customized and specific treatments based on the same.

Key Segments Profiled in the IgA Nephropathy Market Survey

Diagnosis:

Iothalamate Clearance Test
Kidney Biopsy
Blood Tests
Urine Tests

Diseases Type:

Primary IgA Nephropathy
Secondary IgA Nephropathy

Systems:

Hematuria
Proteinuria
Edema
Others

Population Type:

Pediatrics
Adults

Route of Administration:

Oral
Parenteral
Others

Buy This Report: https://www.futuremarketinsights.com/checkout/16217

Treatment:

Medication
Statin therapy
Omega-3 fatty acids
Angiotensin-converting enzyme (ACE) inhibitors
Angiotensin receptor blockers (ARBs)
Diuretics
Immunosuppressants
Kidney Transplantation
Others

End Users:

Hospitals
Specialty Clinics
Homecare
Others

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI is the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Chronic Obstructive Pulmonary Disease Market is projected to grow at a 4.4% CAGR and reach USD 33.19 Billion by 2033 | FMI

The fight against Chronic Obstructive Pulmonary Disease (COPD) requires a multi-faceted approach, and the Chronic Obstructive Pulmonary Disease Market is poised for significant growth. According to a recent analysis, the market is expected to reach approximately USD 33.19 billion by 2033, reflecting a Compound Annual Growth Rate (CAGR) of 4.4%. This upward trend comes amidst concerns about rising alcohol use, a known risk factor for COPD.

A Growing Market Reflects Growing Needs:

The increasing prevalence of COPD is driving the demand for effective treatment options. In 2023 alone, the global COPD market is estimated to be worth USD 21.58 billion. This significant value highlights the widespread need for COPD management solutions.

Request a Sample Copy Of This Report!
https://www.futuremarketinsights.com/reports/sample/rep-gb-16215

Additionally, the World Health Organization (WHO) states that the most common cause of COPD is exposure to tobacco smoke both via first hand as well as second-hand smoking. This global increase in the prevalence of COPD is a major factor fueling the growth of the COPD market in the forthcoming years. In addition, the rise in consumption of tobacco among millennials, coupled with the rise in the awareness among population, regarding the use of generic drug are projected to contribute to the revenue share of the chronic obstructive pulmonary disease market shortly.

According to the Centre for Disease Control and Prevention (CDCP), the cost related to COPD in the US were 32.1 $ billion in 2010, and rose to 49 billion by 2020. Hence, the continual growth witnessed in the cases of COPD among population worldwide is a major factor that will intensify the growth of the COPD market over the forecast period.

Key Takeaways from the Chronic Obstructive Pulmonary Disease Market Study

The global Chronic Obstructive Pulmonary Disease (COPD) Market was valued at US$ 20.67 Billion by 2022-end
From 2018 to 2022, the market demand expanded at a CAGR of 2.4%
By Type, the Chronic Bronchitis segment of the market constitutes the bulk of the market with a market share of 43%
By Distribution Channel, the Retail Pharmacies segment dominates the market with a share of 42%
From 2023 to 2033, Chronic Obstructive Pulmonary Disease (COPD) sales are expected to flourish at a CAGR of 4.4%.
By 2033, the market value of Chronic Obstructive Pulmonary Disease (COPD) is expected to reach US$ 33.19 Billion.

Claim Your Discount Today. Contact us for Discount
https://www.futuremarketinsights.com/request-discount/rep-gb-16215

The continual increase in cases of COPD globally, coupled with rising cases of tobacco consumers are the major factors escalating the growth of the Chronic Obstructive Pulmonary Disease (COPD) market shortly, remarks an FMI analyst.

Chronic Obstructive Pulmonary Disease Market Competitive Landscape

Prominent players in the Chronic Obstructive Pulmonary Disease (COPD) market are Almirall, AstraZeneca, Boehringer Ingelheim International GmbH, CHIESI Farmaceutici S.p.A., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc., Kyowa Hakko Kirin, Mylan N.V., Novartis AG, Orion Corporation, Sanofi, Sunovion Pharmaceuticals, Inc. (Sumitomo Dainippon Pharma Co., Ltd.), Teva Pharmaceutical Industries Ltd., Theravance Biopharma, and Verona Pharmaceuticals, among others.

Chronic Obstructive Pulmonary Disease Market Recent Developments:

In June 2022, Verona Pharma, a pharmaceutical company, announced completion of the patient enrolment, with more than 800 subjects involved for its randomized ENHANCE-1 trial. The study will evaluate ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease. It is a critical step for the phase III ENHANCE trial with top-line data expected by the end of the year 2022 and further data from ENHANCE-2 in the third quarter of 2022.
In May 2022, Alembic Pharmaceuticals Ltd, a pharmaceutical company, received final approval from the US health regulator for its generic version of Arformoterol Tartrate inhalation solution indicated for long-term treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease. The approval by the U.S. Food & Drug Administration (USFDA) for the abbreviated new drug application (ANDA) for Arformoterol Tartrate inhalation solution is for strength of 15 mcg (base)/2 mL unit-dose vial.

Get Your Impactful Report Now! Visit for Customization
https://www.futuremarketinsights.com/customization-available/rep-gb-16215

Know More About What the Chronic Obstructive Pulmonary Disease Market Report Covers

Future Market Insights offers an unbiased analysis of the global Chronic Obstructive Pulmonary Disease (COPD) Market, providing historical data for 2018 to 2022 and forecast statistics from 2023 to 2033. To understand opportunities in the Chronic Obstructive Pulmonary Disease (COPD) Market, the market is segmented based on drug class, type, and distribution channel, across five major regions.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization, and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments based on Source, Application, Sales Channel, and End Use over the next 10-years.

Contact Us:

Autoclave Market Set to Reach USD 3.68 Billion by 2034, Driven by a CAGR of 4.7%

The autoclave market, which had an estimated valuation of USD 2.2 billion in 2023, is projected to experience significant growth over the next decade. According to the latest market analysis, the autoclave market is expected to reach a global valuation of USD 3.68 billion by 2034, advancing at a compound annual growth rate (CAGR) of 4.7% from 2024 to 2034..

Autoclaves are vital tools for sterilizing a variety of materials, including pharmaceuticals, lab apparatus, and medical instruments. High-pressure steam is employed to eradicate germs, viruses, fungus, and spores, guaranteeing a sterile atmosphere in many healthcare and research contexts. The market for autoclaves is expanding due to the rising need for sterilization in medical facilities, research labs, and the pharmaceutical industry.

The growing prevalence of hospital-acquired infections (HAIs), strict sterilizing requirements and regulations, and technological breakthroughs in autoclave design and performance are major drivers of market expansion. The market is expanding thanks to innovations such automated systems, energy-efficient models, and portable autoclaves.

Manufacturers, medical facilities, and academic institutions have a lot of opportunity to invest in cutting-edge sterilization technologies and enhance healthcare results globally thanks to the global autoclave market.

Request a report sample to gain comprehensive insights:
https://www.futuremarketinsights.com/reports/sample/rep-gb-12890

Key Features:

Advanced Technology: The Autoclave Market leverages state-of-the-art technologies to deliver efficient and reliable sterilization processes. From steam sterilization to advanced vaporized hydrogen peroxide systems, these autoclaves offer a comprehensive range of sterilization options tailored to the specific needs of healthcare settings.
Enhanced Safety: With a focus on patient and staff safety, autoclaves in the market are equipped with advanced safety features and protocols to ensure the effective sterilization of medical instruments while minimizing the risk of cross-contamination.
Eco-Friendly Solutions: The Autoclave Market also prioritizes sustainability, offering eco-friendly sterilization solutions that minimize water and energy consumption, reduce waste, and promote environmentally responsible practices.
Customized Solutions: Recognizing the diverse requirements of healthcare facilities, the Autoclave Market offers a range of customizable solutions, including various sizes, configurations, and automation options to suit the specific needs of different settings.
Compliance and Validation: Autoclaves in the market adhere to stringent regulatory standards and undergo rigorous testing and validation processes to ensure compliance with industry regulations and guidelines, providing healthcare professionals with confidence in the sterilization process.

Competitive Landscape:

The key differential strategies followed by manufacturers are focusing on the introduction of new technologies, upgrading existing products, and strategic alliances, for the sale and promotion of their products globally. The companies are also entering into mergers and acquisitions with global players to expand their sales footprint and enhanced service to our customers and create additional value for the shareholders.

For instance:

In November 2020, Steris Corporation completed the acquisition of key surgical. The acquisition was carried out to strengthen, complement and expand STERIS’s product offering and global reach.
In October 2020, Steelco S.p.A. added a new compact model Steelco PL40 to its low-temperature sterilizer line, which is targeted at small clinics searching for an efficient system for reprocessing a wide variety of sensitive devices that cannot be sterilized with steam.

Customization Available:
https://www.futuremarketinsights.com/customization-available/REP-GB-12890

Key Companies:

Steris healthcare
Getinge AB
PHC Corporation
Shinva Medical Instruments Co. Ltd.
MELAG Medizintechnik GmbH & Co. KG
Astell Scientific
Consolidated Sterilizer Systems
Tuttnauer
Labtron Equipment
BMT Medical Technology S.R.O.
LTE Scientific
Belimed AG (Metall Zug)
Steelco S.p.A.
Priorclave
ZIRBUS technology GmbH
Rodwell Autoclave Company
Systec GmbH
Matachana
R. Espinar, S.L.
Benchmark Scientific
MMM Group
ERYIGIT Medical Devices
Hanshin Medical
Narang Medical Limited
Celitron Medical Technologies
Amerex Instruments, Inc.
Ningbo Ican Machines

Autoclaves Market by Category

By Product Type:

Gravity Autoclave
Vacuum-induced Autoclave

By Modality:

Floor standing
Bench Top
Wall Mounted
Portable

By Loading Type:

Top Loading
Front Loading
Pass-Through

By Chamber Type:

Cylindrical
Rectangular

By End-User:

Hospitals
Office-Based Clinics
Academic and Research Institutes
Research Laboratories
Pathology Laboratories
Biopharmaceutical Companies
Food and Beverages Companies

By Region:

North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East and Africa (MEA)

Get Full Market Analysis Now: Purchase The Report:
https://www.futuremarketinsights.com/checkout/12890

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Common Warts Market is expected to reach a significant value of USD 1,100 Million by 2033, with a CAGR of 3.6% | FMI Study

The fight against common warts is gaining momentum, with the Common Warts Market projected to reach a value of USD 1.1 billion by 2033. This forecast, according to a new report by Future Market Insights (FMI), reflects a steady growth trajectory with a CAGR (Compound Annual Growth Rate) of 3.6% from 2023 to 2033.

Moreover, the recurrence of the illness after surgery and therapy can be exploited to build a permanent treatment for warts. Furthermore, the market is impacted by a high number of acquisition strategies and firm alliances for developing novel therapies, as well as a rise in investment for R&D. Each form of wart is connected with a separate and specific HPV, which may be created by identifying and creating a tailored vaccination against the virus. Because of the introduction of novel treatment alternatives, the North American market is predicted to account for the greatest revenue share over the projection period.

Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16204

Additionally, higher healthcare spending, as well as the availability of treatment options, would serve to accelerate the speed of market development in this field. Furthermore, increased illness awareness has caused the industry to expand. These factors are projected to fuel revenue growth in the region’s common warts market throughout the forecast period.

Common Warts Market Key Takeaways:

FMI projects the global Common Warts market to expand at a 3.6% value CAGR by 2033
The global Common Warts market is estimated at a market value of US$ 770 Million
The global Common Warts market is expected to garner a market value of US$ 1100 Million
As per Future Market Insights, the Asia Pacific is expected to grow at a CAGR of 3% in the assessment period 2023-2033.
North America is expected to grow at a CAGR of 3.5% in the assessment period 2023-2033.
Europe is expected to grow at a CAGR of 3.3% in the assessment period 2023-2033.
The Salicylic Acid segment is expected to hold the largest market share for common warts in the forecast period 2023-2033.

“In 2021, North America held the biggest market share of the global Common Warts market. During the predicted period, this tendency is likely to continue. The increased knowledge of numerous treatment options, as well as the introduction of new medicines in this area, is expected to drive the growth of the Common Warts market in North America,” says an analyst at FMI

Unlock Tailored Insights: Customize Your Report for Maximum Impact:
https://www.futuremarketinsights.com/customization-available/rep-gb-16204

Common Warts Market Competition

Key players in the common warts market are Nielsen BioSciences, Verrica Pharmaceutical, Aclaris Therapeutics, Inc., KinoPharma, Inc., pHion Therapeutics, Orgenesis, Novan, Cassopeia Pharmaceuticals, Innovax and Torii Pharmaceutical Co. Ltd.

In March 2020, Verrica Pharmaceuticals Inc. and Torii Pharmaceutical Co., Ltd. announced a cooperation and licence agreement to develop and sell product candidates, including VP-102, for a topical formulation of cantharidin for the treatment of molluscum contagiosum and common warts in Japan.

Key Segments:

Common Warts Market by Diagnosis:

Biopsy
Excision

Common Warts Market by Drug Type:

Imiquimod
Silver Nitrate
Glutaraldehyde
Salicylic Acid
Formaldehydel
Aminolevulinic Acid

Common Warts Market by Medication Class:

Topical Retinoids
Oral Retinoids

Author By:

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI is the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Microneedle Drug Delivery Systems Market to Achieve Significant Growth, Projected to Reach USD 1459.1 Million by 2033 with a CAGR of 6.6%

The microneedle drug delivery systems market. According to the report, the market is set to record a compound annual growth rate (CAGR) of 6.6% from 2023 to 2033. The market size, which is projected to reach USD 768.9 million in 2023, is expected to grow significantly to USD 1459.1 million by 2033.

Innovative technologies called microneedle drug delivery systems use hundreds of microneedles placed on a tiny patch to deliver medication. This method guarantees efficient and painless drug administration by directly delivering medication into the viable epidermis without coming into contact with the dermal layers’ blood vessels and nerves.

The microneedles are formed of a variety of materials and have typical dimensions of hundreds of microns for length, 1 to 50 microns for width at the tip, and 50 to 300 microns for base. These substances include polymers, carbohydrates, silicon, silica glass, and ceramics; each has special qualities that improve the efficiency of microneedle drug delivery systems.

Microneedle technology is becoming more and more popular due to its many benefits, which include less invasiveness, less pain, and better patient compliance. This technology is an essential feature of contemporary medical therapies since it makes administering insulin, vaccinations, and other medicinal chemicals easier.

Request a report sample to gain comprehensive insights:
https://www.futuremarketinsights.com/reports/sample/rep-gb-2750

Key Takeaways from the Report

Solid microneedles are expected to lead the market during forecast period of 2020-2030 among product type
Hospitals are the leading end users of microneedle drug delivery systems, with specialty clinics gaining popularity.
Specialty clinics are expected to grow at an accelerated rate as one of the key end users of microneedle drug delivery systems
North America is the largest market for microneedle drug delivery systems. Along with Europe, it is expected to cover more than 70% of the market by end of 2030.
East Asia is expected to be the fastest-growing regional market during the next decade.

“Companies operating in the market are leaving no stone unturned to introduce innovations. Some have even tied up with leading solutions provider to commercialize their innovations once approved. This is expected to pave way for the market’s growth in the near future” said a lead Analyst at FMI.

Covid 19 Restricting Pace of Growth

The onset of pandemic has disturbed the entire business ecosystem. With productions coming to a halt and supply chains disrupted due to lack of transport, manufacturers of microneedle drug delivery systems are impacted in a big way.

Also, because of several restrictions by governments like social distancing, doctors and practitioners are choosing to avoid any surgical treatments which are not absolutely and immediately necessary.

Furthermore, cosmetic field which is another major user of microneedle drug delivery systems is also impacted as almost all treatments under their umbrella are considered to be not urgent.

Customization Available:
https://www.futuremarketinsights.com/customization-available/REP-GB-2750

Key Players:

3M Company, Becton, Dickinson and Company, Zosano Pharma Corporation, Raphas co. ltd., Nanopass Tech, Corium International, Inc., Valeritas, Inc., Nitto Denko Corporation, Microdermics, Inc., TheraJect Inc., Vaxxas Pty Ltd., Endoderma Ltd., QuadMedicine, SNvia Co., Ltd., Small Lab and AdminMed Nano BioSciences LLC

Consolidating their positions through mergers, acquisitions and new product launches, global microneedle drug delivery systems market players rely heavily on new product innovation and differentiation for gaining an edge over their competitors.

The market is poised to grow during the forecast period owing to the increasing cases of diseases and needle phobia among patients. However, changing regulatory dynamics are expected to affect the growth of microneedle drug delivery systems market in the future.

For instance, Zosano Pharma’s clinical trial of zolmitriptan with microneedle drug delivery system was stopped by U. S. Food and Drug Administration because inconsistencies were found in the drug delivery.

To Know More about Heat induction Cap liner Market:

Future Market Insights (FMI) brings the comprehensive research report on forecast revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2015 to 2030. The global microneedle drug delivery systems market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on microneedle drug delivery systems market on the basis of product type such as solid microneedles, hollow microneedles and dissolving microneedles. Based on end-user such as hospitals, ambulatory centers, specialty clinics, academic institutes and research institutes across seven major regions

Get Full Market Analysis Now: Purchase The Report:
https://www.futuremarketinsights.com/checkout/2750

Key Segments

Product Type

Solid Microneedles
- Silicon
- Metal
- Polymer
Hollow Microneedles
Dissolving Microneedles

End User

Hospitals
Ambulatory Surgical Centers
Specialty Clinics
Academic Institutions
Research institutes

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Human Immunodeficiency Virus Type 1 (HIV 1) Market is predicted to be valued USD 62.37 Billion by 2033, at a CAGR of 6% | FMI

Despite advancements in managing HIV, the Human Immunodeficiency Virus Type 1 (HIV 1) Market is expected to reach a substantial USD 34.83 billion by 2033, according to a new report. This reflects a projected Compound Annual Growth Rate (CAGR) of 6% from 2023 to 2033. The Institute for Health Metrics and Evaluation attributes this growth to the persistent, and relatively unchanged, incidence rate of HIV-1 infection globally.

It affected approximately 37 million people worldwide. Furthermore, antiretroviral therapeutic interventions for disease management are only available to half of this population. HIV-1 is the more common of the two types of human immunodeficiency virus, accounting for approximately 96% of all infections globally. The prevalence of HIV is rising at an alarming rate.

The World Health Organization (WHO) estimates that 33.0 million individuals are infected with HIV. This has heightened public awareness, which is directing to an increase in testing procedures. This will cause an increase in demand for HIV medicines with greater efficacy for treatment and care over the projected period.

Request a Sample of this Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-16202

Because of the large percentage of HIV patients in highly populous countries such as China and India, the Asia Pacific market is expected to become the fastest-growing market with the highest CAGR over the coming years. Furthermore, the massive amount of therapeutic interventions, as well as monetary support from corporate companies and medical companies, are anticipated to propel the industry forward.

Key Takeaways from Human Immunodeficiency Virus Type 1 (HIV 1) Market Study

North America led the market in 2022, with a sales volume of US$ 21 Billion.
According to a study conducted by the Centers for Disease Control (CDC) in 2021, an estimated 1.2 million people had HIV at the end of 2018.
Based on the World Health Organization (WHO), approximately 33.0 million people were infected with HIV by 2021.
Women and girls comprised 54% of all HIV-positive people, according to the WHO.
From 2018 to 2022, sales increased significantly at a CAGR of 1.6%.

Key Market Players

Key players in the Human Immunodeficiency Virus Type 1 (HIV 1) market are AbbVie, Inc., Boehringer, Ingelheim GmbH. Bristol-Myers Squibb Company, Cipla, Inc, Genentech, Inc, Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare, GlaxoSmithKline, Sanofi.

In July 2021 – Unitaid and the Clinton Health Access Initiative, Inc. (CHAI) announced a pricing agreement with the medical company Hetero Labs LTD to make darunavir plus ritonavir (DRV/r) available as a second-line treatment for HIV patients in low and middle-income countries for US$ 210 per patient/year.
In March 2021, Gilead Sciences Inc and Merck announced a collaboration agreement to co-develop and co-commercialize long-term HIV treatment. The investigational capsid inhibitor lenacapavir from Gilead and the investigational nucleoside reverse transcriptase translocation inhibitor islatravir from Merck will be paired to form a two-drug HIV regimen.
On January 20, 2021 – HIV ViiV Healthcare evolved Cabenuva, an injectable drug approved by the US Food and Drug Administration for the treatment of human immunodeficiency virus type 1 (HIV) infections in adults.

Request for Customization: https://www.futuremarketinsights.com/customization-available/rep-gb-16202

Key Segments Profiled in the Human Immunodeficiency Virus Type 1 (HIV 1) Market Industry Survey

Human Immunodeficiency Virus Type 1 (HIV 1) Market by Drug Class:

Nucleoside-Analog Reverse Transcriptase Inhibitor
Non-Nucleoside Reverse Transcriptase Inhibitor
Entry and Fusion Inhibitors
Protease Inhibitors
Integrase Inhibitors
Coreceptor Antagonists

Author By:

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Contact Us:

Kinase Inhibitor in Autoimmune Diseases Market is Expecting a Growth and a Potential Value of USD 80,252 Million by 2033, at a CAGR of 5.4% | FMI

The fight against autoimmune diseases is gaining a powerful ally: Kinase Inhibitor in Autoimmune Diseases Market is projected to experience significant growth, with a revenue of USD 80,252 million anticipated by 2033. This impressive figure marks a substantial jump from the predicted USD 47,430 million in 2023, reflecting a robust compound annual growth rate (CAGR) of 5.4%.

Autoimmune diseases have garnered increasing attention due to the rising awareness among individuals and healthcare professionals. As a result, healthcare spending is on the upswing, providing a conducive environment for the expansion of the kinase inhibitor market in the autoimmune diseases sector.

Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16171

Kinase Inhibitor in Autoimmune Diseases Market Key Factors:

Technological Advancements: Technological progress in the healthcare industry has paved the way for innovative treatments, including kinase inhibitors, which are proving to be effective in managing autoimmune diseases.
Increasing Awareness: Growing awareness among both patients and healthcare providers about autoimmune diseases, their diagnosis, and treatment options is leading to earlier intervention and treatment, driving market growth.
Rising Healthcare Spending: With a greater focus on healthcare, there has been a surge in healthcare spending worldwide. This increased investment is facilitating the development and adoption of advanced therapies for autoimmune diseases.

Competitive Environment:

The expert survey study closely examines the business practises, executive summaries, and operational dynamics of the top producers and participants in the global kinase inhibitor market for autoimmune illnesses. It evaluates its range of products, prospects for growth, sales, revenue, and profitability throughout the projection.

In the global kinase inhibitor market for autoimmune treatments, Pfizer, Reistone Biopharma, Eli Lily and Incyte Corporation, AbbVie, Gilead Sciences, Astellas Pharma, Japan Tobacco and Torii Pharmaceutical, Incyte Corporation, Bristol Myers Squibb, Galapagos NV, and other prominent players are some of the top manufacturers and players evaluated.

Producers and participants operating within the worldwide kinase inhibitor market for autoimmune disorders are implementing diverse business expansion tactics, including the introduction of new products, mergers and acquisitions, and expansion into new areas, among other things.

December 2022: An exclusive global collaboration and option to licence agreement for HotSpot’s discovery-stage IRF5 programme for the treatment of autoimmune diseases was announced by AbbVie and HotSpot Therapeutics, Inc., a biotechnology company that is leading the discovery and development of small molecule allosteric therapies for the treatment of cancer and autoimmune diseases.
Reistone Biopharma, a company dedicated to creating therapies for illnesses linked to inflammation and the immune system, revealed encouraging top-line findings in August 2021 from a Phase 2 study assessing the efficacy and safety of once-daily SHR0302 in adults with alopecia areata (AA). The safety of the treatment was comparable to that of other JAK1 inhibitors, and it was well tolerated. An autoimmune condition called AA can result in patchy or total hair loss, which can have a significant psychological impact.

Key Companies:

Pfizer
Reistone Biopharma
Eli Lily and Company
AbbVie
Gilead Sciences
Astellas Pharma
Japan Tobacco and Torii Pharmaceutical
Incyte Corporation
Bristol Myers Squibb
Galapagos NV

Unlock Tailored Insights: Customize Your Report for Maximum Impact:
https://www.futuremarketinsights.com/customization-available/rep-gb-16171

Key Segments:

Kinase Inhibitor in Autoimmune Diseases Market by Treatment:

Physical therapy
Treatment of Deficiency
Surgery

Kinase Inhibitor in Autoimmune Diseases Market by Drug:

Anti-inflammatory Drugs
Corticosteroids
Pain-killing Medications
Immunosuppressants

Kinase Inhibitor in Autoimmune Diseases Market by Region:

North America
Latin America
Europe Kinase
Asia Pacific
Middle East & Africa

Author By:

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Contact Us:

Pancreatic Cancer Market is expected to surpass USD 7,541.09 Million by 2033, growing at a 13.5% annual rate | FMI Study

The fight against pancreatic cancer receives a significant boost as the market for treatment solutions experiences impressive growth. According to industry estimates, the Pancreatic Cancer Market is poised to reach a value of approximately USD 2.13 billion in 2023. This momentum is predicted to continue, with the market projected to surge at a robust Compound Annual Growth Rate (CAGR) of 13.5%. This translates to a staggering market value exceeding USD 7.54 billion by 2033.

Pancreatic cancer, a prevalent and pressing concern, ranks as one of the most frequently diagnosed types of cancer and is currently the seventh leading cause of cancer-related fatalities on a global scale. Notably, the incidence of pancreatic cancer is on the rise, with a pronounced increase observed, particularly in the Western world. Developed regions, in particular, are witnessing a surge in cases of pancreatic adenocarcinoma, with lifestyle factors such as alcohol consumption and obesity playing significant roles in driving this upward trend.

Request a Sample Copy of the Report Now.
https://www.futuremarketinsights.com/reports/sample/rep-gb-16183

Why Choose Future Market Insights

Serving domestic and international clients 24/7
Prompt and efficient customer service
Data collected from reliable primary and secondary sources
Highly trained and experienced team of research analysts
Seamless delivery of tailor-made market research reports

Pancreatic Cancer Market: Segmentation

Valuable information covered in the FMI’s Pancreatic Cancer market report has been segregated into key segments and sub-segments.

By Treatment Type:

Chemotherapy
Immunotherapy
Hormone Therapy
Surgery
Radiation Therapy
Targeted Drug Therapy
Others

Grab Your Discount Now Before It Is Gone!
https://www.futuremarketinsights.com/request-discount/rep-gb-16183

By Cancer Type:

Endocrine Pancreatic Cancer
Exocrine Pancreatic Cancer

By End User:

Hospitals
Clinics
Diagnostic Laboratories
Research Institutes
Research Laboratories
Others

Pancreatic Cancer Market: Competition Analysis

The FMI’s study presents a comprehensive analysis of global, regional, and country-level players active in the Pancreatic Cancer market. Competitive information detailed in the Pancreatic Cancer market report has been based on innovative product launches, distribution channels, local networks, industrial penetration, production methods, and revenue generation of each market player. Furthermore, the Pancreatic Cancer market report includes growth strategies and mergers & acquisitions (M&A) activities associated with the players.

Key players covered in the report include:

Pfizer Inc.
Novartis AG
Eli Lily and Company
Bristol Myers Squibb Company
Zydus Cadila
Myriad Genetics Inc.
F-Hoffmann-La Roche Ltd.
PharmaCyte Biotech Inc.
Teva Pharmaceutical Industries Ltd.

Get Your Customized Impactful Report Now!
https://www.futuremarketinsights.com/customization-available/rep-gb-16183

Important Questions Answered in the Pancreatic Cancer Market Report

Which end user remains the top revenue contributor in different regional markets?
At what rate has the global Pancreatic Cancer market been expanding during the forecast period?
How will the global Pancreatic Cancer market look like by the end of the forecast period?
What innovative strategies are adopted by Pancreatic Cancer market players to stay ahead of the pack?
What are the restraints affecting the growth of the global Pancreatic Cancer market?

Key Offerings of the Report

Growth Drivers and Opportunities: Comprehensive analysis on growth-driving factors and opportunities for market players in different regional markets
Recent Trends and Forecasts: Detailed assessment on the latest trends, technological developments, and forecasts for a 5-year or 10-year period.
Segmental Analysis: Extensive analysis on each segment and factors differentiating the role of these segments in market revenue forecasts and growth rate analysis
Regional Market Forecast: Thorough analysis of each regional market to arm stakeholders with the necessary information to take critical decisions
Competitive Landscape: All-inclusive insights on both leading and emerging players vying for a slice of the Pancreatic Cancer market

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Non-Small Cell Lung Carcinoma Market is expected to reach USD 21.40 Billion by 2033, Driven by a 10% CAGR | FMI

The fight against Non-Small Cell Lung Carcinoma Market, the most common type of lung cancer, is bolstered by a growing market for treatment options. According to a recent analysis, the global NSCLC market is projected to reach a significant USD 21.4 billion by 2033. This reflects a substantial increase from a market value of USD 8.25 billion in 2023, translating to a robust Compound Annual Growth Rate (CAGR) of 10%.

With the latest insights and statistics from the biggest pharmaceutical and healthcare device manufacturers across the globe, FMI presents an extensive analysis of Non-Small Cell Lung Carcinoma (NSCLC) market.

FMI offers insights into the market data on over 5000+ drugs from more than 100 countries, which further aids the research on current and upcoming market scenarios for the Non-Small Cell Lung Carcinoma (NSCLC) market. Our expert researchers and analysts for healthcare tracks the data of established players as well as new entrants in the medical industry to provide an unbiased analysis for a sound and financial decision.

Request a Sample PDF Copy of This Report!
https://www.futuremarketinsights.com/reports/sample/rep-gb-16180

Over the past decade, the healthcare sector has been expanding remarkably, following the advent of artificial Intelligence and the Internet of Things integrated medical devices. Advancements in technology have created impressive scope within the medical sector for diagnostics and therapeutics.

The report offers extensive data sets validating key trends impacting growth in the Non-Small Cell Lung Carcinoma (NSCLC) market. It offers insights into strategies adopted by the key players and addresses the concerns that will challenge the growth of the Non-Small Cell Lung Carcinoma (NSCLC) market. With our extensive research and information about the past, current, and future market scenario, the Non-Small Cell Lung Carcinoma (NSCLC) market report will help and identify the concerns, for a smooth sail of small & medium as well as large enterprises.

Critical Questions Answered in the Report

What are ongoing trends that will shape the market growth curve for the global Non-Small Cell Lung Carcinoma (NSCLC) market?
What are the drivers and challenges affecting the Non-Small Cell Lung Carcinoma (NSCLC) market demand?
What are the recent technological advancements in the Non-Small Cell Lung Carcinoma (NSCLC) market?
What are key trends and opportunities that will prevail in the revenue growth of Non-Small Cell Lung Carcinoma (NSCLC) market players?
How will evolving regulatory policies impact market growth?
What is the impact of Covid-19 on the Non-Small Cell Lung Carcinoma (NSCLC) market?

Non-Small Cell Lung Carcinoma Market: Segmentation

By Region

North America
Latin America
Europe
South Asia & Pacific
East Asia
Middle East & Africa

Detailed analysis of the geographical region and country-wise insights are offered in the latest Non-Small Cell Lung Carcinoma (NSCLC) market report with established market players as well as incumbents in the region.

Key Segments Profiled in the Non-Small Cell Lung Carcinoma Market Survey

Type:

Adenocarcinoma
Squamous Cell Carcinoma
Large Cell Carcinoma
Large Cell Neuroendocrine Tumors

Get a Report Customization Now!
https://www.futuremarketinsights.com/customization-available/rep-gb-16180

Treatment:

Chemotherapy
Targeted Therapy
- Bevacizumab (Avastin)
- Nectiumumbab (Portrazza)
- Ramucirumab (Cyramza)
Immunotherapy
- Nivolumab (Opdivo)
- Atezolizumab (Tecentrig)
Others

End User:

Hospitals
Homecare
Specialty Clinics
Others

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments based on Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:

Ice Cream and Frozen Dessert Market is projected to grow at a CAGR of 7.50%, reaching USD 2,83,900.20 million by 2034

Ice cream and frozen desserts have been consumed in our society from the beginning of time. Even during the pandemic, this consumption didn’t plunge, instead, it underwent a rapid surge. The Ice Cream and Frozen Desserts market is valued at US$ 1,38,300 million, as of 2024, has a promising future ahead, thanks to the emergence of artisanal ice cream and DIY parlors in developing and developed economies.

With the growing health-consciousness among the general population, people are increasingly opting for probiotic yogurts and zero-calorie frozen desserts. This is very likely to push the market size to a staggering US$ 283900.2 million by 2034. Consumption has also seen a noticeable surge since people are using protein-rich yogurts as their pre and post-workout meals.

The growing lactose-intolerant population hasn’t really affected the overall progress of this market as brands came up with non-dairy alternatives of people’s favorite flavors and textures. The market is still slated to grow at a healthy CAGR of 7.50% through 2034. Besides this, plant-based and gourmet ice cream options are gradually taking their place in the affluent population’s shopping list.

Request Sample Report and Drive Impactful Decisions: https://www.futuremarketinsights.com/reports/sample/rep-gb-912

Key Takeaways from the Market Study

The ice cream segment dominates the global ice cream and frozen dessert market with a share of 87.30% in 2024.
Based on distribution channels, the hypermarket/supermarkets lead the ice cream and frozen dessert market with a share of 56.90% in 2024.
The ice cream and frozen dessert market in China is anticipated to grow at a CAGR of 3.50% through 2034.
The ice cream and frozen dessert market in Germany is estimated to rise at a 7.00% CAGR through 2034.
The ice cream and frozen dessert market in the United States has the potential to increase at 4.10% CAGR through 2034.
The Japanese ice cream and frozen dessert market is predicted to rise by 4.70% CAGR through 2034.
The ice cream and frozen dessert market in India is very likely to grow at a CAGR of 8.20% through 2034.

“The emergence of food delivery platforms has substantially affected the ice cream and frozen dessert market in a positive manner. Brands must leverage these platforms to reach a wider consumer base,” opines an FMI analyst.

Competitive Landscape

The market for ice creams and frozen desserts is highly competitive with both international and domestic brands vying for dominance.
The emergence of local and artisanal ice cream parlors has diverted a substantial part of the consumer base.
Some of the prominent companies in the market include Baskin-Robbins, Nestle SA, Unilever, Danone Groupe SA, Ben & Jerry’s Homemade Holdings Inc., Cielo USA, Breyers Ice Cream, Casper’s Ice Cream, etc.
These companies have a loyal consumer base due to their prolonged presence in the market.
The sales of probiotic yogurts and low-calorie frozen desserts are likely to experience a surge due to increasing awareness of dietary habits.
Brands are focusing on premium branding and aesthetic packaging to attract the millennial population.

Recent Developments:

Oreo, in March 2024, released a new line of mint-flavored frozen treats with mint creme-flavored dairy desserts and Oreo cookie pieces.
In February 2024, Katoomba Global Foods launched a premium Indian kulfi ice cream range with Australia-made kulfi and India’s Parle G biscuits.
Häagen-Dazs introduced oat-based, vegan-certified frozen desserts in Canada with creamy texture and indulgent flavors in May 2023.
Snoop Dogg and Happi Co., in July 2023, launched Dr. Bombay Ice Cream, inspired by his NFT character, in 3,500 Walmart stores.
Oatly and Carvel partnered to offer dairy-free options nationwide including strawberry soft serve, cookies and cream, and frozen dessert cakes in January 2024.

Gain Immediate Access to Detailed Market Insights Purchase Now: https://www.futuremarketinsights.com/checkout/912

Key Segments Covered in the Ice Cream and Frozen Dessert Industry Analysis

By Type:

Frozen Yogurt
Frozen Cakes
Ice Cream
Others

By Distribution Channel:

Supermarkets/Hypermarkets
Convenience Stores
Specialty Stores
Others

By Region:

North America
Latin America
Europe
Asia Pacific
Middle East and Africa (MEA)

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact FMI:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube